Rouda Feder Tietjen & McGuinn is investigating claims of patients who have experienced uncontrollable bleeding associated with Pradaxa. Pradaxa, also known generically as Dabigatran, is a blood-thinning medication that has been prescribed to over 850,000 patients in the United States. Pradaxa is commonly prescribed to patients who have an irregular heartbeat due to atrial fibrillation, not caused by valvular disease.
Boehringer Ingelheim, the manufacturer of Pradaxa, received FDA approval in 2010. The drug is marketed as a convenient alternative to Warfarin (Coumadin, Jantoven) because Pradaxa does not require weekly blood testing, unlike the other anticoagulants.
However, Pradaxa has been linked to 542 deaths and nearly 2,400 hemorrhages in 2011, compared to Warfarin’s 72 deaths during the same period. These deaths and injuries are attributed to a dangerous risk of uncontrollable bleeding and the inability to reverse Pradaxa’s anticoagulant properties.
Filing a lawsuit against Boehringer Ingelheim, the drug manufacturer, may secure damages that will cover:
- Medical expenses, both past and future
- Loss of earnings, both past and future
- Pain and suffering, including mental anguish and physical impairments
- And in the case of wrongful death, funeral costs and other loss
If you or a loved one have taken Pradaxa and suffered a bleeding injury, please contact us to discuss your legal rights. Our conversation is free, and we will represent you at no cost unless we prevail.